Xeris Pharmaceuticals Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 03 2025
0mins
Should l Buy XERS?
Source: Yahoo Finance
Employee Stock Grants: Xeris Biopharma Holdings granted 382,975 restricted stock units to 40 new employees as part of its Inducement Equity Plan, effective October 1, 2025.
Company Overview: Xeris is a biopharmaceutical company focused on developing innovative therapies, with three commercially available products and a pipeline that includes a Phase 3-ready treatment for hypothyroidism.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XERS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XERS
Wall Street analysts forecast XERS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.910
Low
9.00
Averages
9.67
High
10.00
Current: 6.910
Low
9.00
Averages
9.67
High
10.00
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Xeris Biopharma to Release 2025 Financial Results
- Earnings Release Schedule: Xeris Biopharma Holdings will announce its fourth quarter and full year 2025 financial results before the U.S. market opens on March 2, 2026, highlighting its ongoing growth and innovation in the biopharmaceutical sector.
- Conference Call Timing: Management will host a conference call and webcast at 8:30 a.m. ET on that day to discuss the company's financial and operational results, aiming to enhance investor understanding and confidence in the company's performance.
- Registration Participation Method: Investors can pre-register for the conference call via the provided link, with a recommendation to register at least ten minutes in advance to ensure smooth participation, reflecting the company's commitment to investor relations.
- Product and Pipeline Overview: Xeris currently has three commercially available products, including Recorlev® for Cushing's syndrome, Gvoke® for severe hypoglycemia, and Keveyis® for primary periodic paralysis, along with multiple development programs like XP-8121, showcasing its robust product pipeline and market potential.
See More
Xeris Biopharma to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Xeris Biopharma will announce its Q4 and full-year 2025 financial results before the U.S. market opens on March 2, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call at 8:30 a.m. Eastern Time to discuss financial and operational results, aiming to enhance investor understanding and confidence in the company's performance.
- Product Line Overview: Xeris currently has three commercially available products, including Recorlev® for Cushing's syndrome, Gvoke® for severe hypoglycemia, and Keveyis® for primary periodic paralysis, indicating a diversified portfolio in the biopharmaceutical sector.
- R&D Pipeline Progress: Xeris's pipeline includes XP-8121, a Phase 3-ready once-weekly subcutaneous injection for hypothyroidism, showcasing the company's potential in addressing thyroid disorders and further solidifying its market position.
See More
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
- ETF Upside Potential: The iShares U.S. Pharmaceuticals ETF (IHE) has an implied analyst target price of $96.28 per unit, while trading at $86.15, indicating an 11.76% upside, reflecting market optimism about the ETF's future performance.
- MBX Stock Analysis: MBX BIOSCIENCES INC (MBX) trades at $35.83, with an analyst target price of $60.55, suggesting a potential upside of 69.01%, showcasing investor confidence in its future prospects.
- CRNX Stock Outlook: Crinetics Pharmaceuticals Inc (CRNX) has a current price of $51.32 and an analyst target of $83.46, indicating a 62.63% upside, reflecting positive market sentiment regarding its product and R&D advancements.
- XERS Investment Opportunity: Xeris Biopharma Holdings Inc (XERS) is priced at $7.14, with an analyst target of $11.14, showing a 56.05% upside, indicating analysts' optimism about its growth potential.
See More
Xeris Anticipates 2025 Revenue of $292 Million, Exceeding Guidance
- Revenue Growth: Xeris anticipates total revenue of $292 million for 2025, exceeding the guidance range of $285-$290 million and reflecting a 44% increase from the previous year, indicating strong market demand and product performance.
- Product Performance: Recorlev® achieved net revenue of $45 million in Q4 2025 and $139 million for the full year, demonstrating increasing market acceptance in treating endogenous Cushing's syndrome.
- Patient Base Expansion: By the end of 2025, approximately 700 patients were on Recorlev® therapy, while Gvoke® saw revenue growth of over 13% year-over-year, showcasing the company's success in patient treatment and market penetration.
- Financial Stability: Xeris delivered positive adjusted EBITDA in every quarter, reinforcing the company's financial foundation and positioning it for sustained growth in the future.
See More
Outlook Therapeutics Inc Faces 60.9% Drop After FDA Response on ONS-5010
- FDA Rejection: Outlook Therapeutics Inc's resubmission for the ONS-5010 biologics license application received a complete response letter from the FDA, indicating that the application cannot be approved in its current form, leading to a 60.9% drop in pre-market trading to $0.62, severely impacting investor confidence.
- Severe Market Reaction: The significant decline in Outlook Therapeutics' stock price reflects market concerns over its future product development prospects, which may hinder financing efforts and delay research progress.
- Other Stock Movements: In pre-market trading, Intelligent Bio Solutions Inc's stock fell 19.2% to $7.70 following the announcement of a $10 million private placement, indicating a decreased risk appetite among investors in the biotech sector.
- Overall Market Trend: While Nasdaq 100 futures rose about 1%, several stocks showed weakness in pre-market trading, suggesting that investor sentiment in the biotech sector is shaken, which could affect overall market mood.
See More
Xeris Biopharma Shares Surge 7.59% as Competitor Corcept's FDA Approval Fails
- Stock Surge: Xeris Biopharma's shares rose 7.59% on Wednesday following the news that competitor Corcept Therapeutics' drug failed to gain FDA approval, reflecting investor confidence in Xeris's existing medication, Recorlev, which is expected to further solidify its market position.
- Market Potential: Analyst Glen Santangelo reiterated a buy rating on Xeris with a $10 price target, highlighting that the addressable market for Cushing's disease could grow from the current $1 billion to $3 billion by 2030, indicating significant growth potential for Xeris in this sector.
- FDA Decision Impact: Corcept's relacorilant was not approved by the FDA due to insufficient evidence of effectiveness, a decision that will reduce competition for Xeris's Recorlev, thereby enhancing its sales outlook.
- Clinical Trial Challenges: Although Corcept has vowed to continue pursuing approval, this will likely require additional clinical trials, potentially delaying its market entry and providing Xeris with more time and space to expand its market share.
See More
Xeris Biopharma to Release 2025 Financial Results
- Earnings Release Schedule: Xeris Biopharma Holdings will announce its fourth quarter and full year 2025 financial results before the U.S. market opens on March 2, 2026, highlighting its ongoing growth and innovation in the biopharmaceutical sector.
- Conference Call Timing: Management will host a conference call and webcast at 8:30 a.m. ET on that day to discuss the company's financial and operational results, aiming to enhance investor understanding and confidence in the company's performance.
- Registration Participation Method: Investors can pre-register for the conference call via the provided link, with a recommendation to register at least ten minutes in advance to ensure smooth participation, reflecting the company's commitment to investor relations.
- Product and Pipeline Overview: Xeris currently has three commercially available products, including Recorlev® for Cushing's syndrome, Gvoke® for severe hypoglycemia, and Keveyis® for primary periodic paralysis, along with multiple development programs like XP-8121, showcasing its robust product pipeline and market potential.
See More
Xeris Biopharma to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Xeris Biopharma will announce its Q4 and full-year 2025 financial results before the U.S. market opens on March 2, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call at 8:30 a.m. Eastern Time to discuss financial and operational results, aiming to enhance investor understanding and confidence in the company's performance.
- Product Line Overview: Xeris currently has three commercially available products, including Recorlev® for Cushing's syndrome, Gvoke® for severe hypoglycemia, and Keveyis® for primary periodic paralysis, indicating a diversified portfolio in the biopharmaceutical sector.
- R&D Pipeline Progress: Xeris's pipeline includes XP-8121, a Phase 3-ready once-weekly subcutaneous injection for hypothyroidism, showcasing the company's potential in addressing thyroid disorders and further solidifying its market position.
See More
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
- ETF Upside Potential: The iShares U.S. Pharmaceuticals ETF (IHE) has an implied analyst target price of $96.28 per unit, while trading at $86.15, indicating an 11.76% upside, reflecting market optimism about the ETF's future performance.
- MBX Stock Analysis: MBX BIOSCIENCES INC (MBX) trades at $35.83, with an analyst target price of $60.55, suggesting a potential upside of 69.01%, showcasing investor confidence in its future prospects.
- CRNX Stock Outlook: Crinetics Pharmaceuticals Inc (CRNX) has a current price of $51.32 and an analyst target of $83.46, indicating a 62.63% upside, reflecting positive market sentiment regarding its product and R&D advancements.
- XERS Investment Opportunity: Xeris Biopharma Holdings Inc (XERS) is priced at $7.14, with an analyst target of $11.14, showing a 56.05% upside, indicating analysts' optimism about its growth potential.
See More
Xeris Anticipates 2025 Revenue of $292 Million, Exceeding Guidance
- Revenue Growth: Xeris anticipates total revenue of $292 million for 2025, exceeding the guidance range of $285-$290 million and reflecting a 44% increase from the previous year, indicating strong market demand and product performance.
- Product Performance: Recorlev® achieved net revenue of $45 million in Q4 2025 and $139 million for the full year, demonstrating increasing market acceptance in treating endogenous Cushing's syndrome.
- Patient Base Expansion: By the end of 2025, approximately 700 patients were on Recorlev® therapy, while Gvoke® saw revenue growth of over 13% year-over-year, showcasing the company's success in patient treatment and market penetration.
- Financial Stability: Xeris delivered positive adjusted EBITDA in every quarter, reinforcing the company's financial foundation and positioning it for sustained growth in the future.
See More
Outlook Therapeutics Inc Faces 60.9% Drop After FDA Response on ONS-5010
- FDA Rejection: Outlook Therapeutics Inc's resubmission for the ONS-5010 biologics license application received a complete response letter from the FDA, indicating that the application cannot be approved in its current form, leading to a 60.9% drop in pre-market trading to $0.62, severely impacting investor confidence.
- Severe Market Reaction: The significant decline in Outlook Therapeutics' stock price reflects market concerns over its future product development prospects, which may hinder financing efforts and delay research progress.
- Other Stock Movements: In pre-market trading, Intelligent Bio Solutions Inc's stock fell 19.2% to $7.70 following the announcement of a $10 million private placement, indicating a decreased risk appetite among investors in the biotech sector.
- Overall Market Trend: While Nasdaq 100 futures rose about 1%, several stocks showed weakness in pre-market trading, suggesting that investor sentiment in the biotech sector is shaken, which could affect overall market mood.
See More
Xeris Biopharma Shares Surge 7.59% as Competitor Corcept's FDA Approval Fails
- Stock Surge: Xeris Biopharma's shares rose 7.59% on Wednesday following the news that competitor Corcept Therapeutics' drug failed to gain FDA approval, reflecting investor confidence in Xeris's existing medication, Recorlev, which is expected to further solidify its market position.
- Market Potential: Analyst Glen Santangelo reiterated a buy rating on Xeris with a $10 price target, highlighting that the addressable market for Cushing's disease could grow from the current $1 billion to $3 billion by 2030, indicating significant growth potential for Xeris in this sector.
- FDA Decision Impact: Corcept's relacorilant was not approved by the FDA due to insufficient evidence of effectiveness, a decision that will reduce competition for Xeris's Recorlev, thereby enhancing its sales outlook.
- Clinical Trial Challenges: Although Corcept has vowed to continue pursuing approval, this will likely require additional clinical trials, potentially delaying its market entry and providing Xeris with more time and space to expand its market share.
See More
